Brian Druker
MD
Director, OHSU Knight Cancer Institute
👥Biography 个人简介
Brian Druker developed imatinib (Gleevec) for chronic myeloid leukemia, proving that molecularly targeted therapy could achieve dramatic and durable remissions. His success with BCR-ABL inhibition transformed CML from a fatal disease to a manageable chronic condition and catalyzed the era of precision oncology. Imatinib remains the paradigmatic example of rational drug design in cancer medicine.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Brian Druker 的研究动态
Follow Brian Druker's research updates
留下邮箱，当我们发布与 Brian Druker（Oregon Health & Science University）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment